1. Market Research
  2. > Disruptive Behavior Disorder – Pipeline Review, H1 2013

Disruptive Behavior Disorder – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 154 pages

Disruptive Behavior Disorder – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Disruptive Behavior Disorder - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Disruptive Behavior Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Disruptive Behavior Disorder. Disruptive Behavior Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Disruptive Behavior Disorder.
- A review of the Disruptive Behavior Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Disruptive Behavior Disorder pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Disruptive Behavior Disorder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Disruptive Behavior Disorder pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Disruptive Behavior Disorder - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Disruptive Behavior Disorder Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Disruptive Behavior Disorder 9
Disruptive Behavior Disorder Therapeutics under Development by Companies 11
Disruptive Behavior Disorder Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Disruptive Behavior Disorder Therapeutics - Products under Development by Companies 19
Disruptive Behavior Disorder Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Disruptive Behavior Disorder Therapeutics Development 23
DURECT Corporation 23
Johnson and Johnson 24
AstraZeneca PLC 25
Eli Lilly and Company 26
Athersys, Inc. 27
Dainippon Sumitomo Pharma Co., Ltd. 28
Taisho Pharmaceutical Co., Ltd. 29
Egalet a/s 30
Pfizer Inc. 31
Shire Plc 32
Collegium Pharmaceutical, Inc. 33
Bionomics Limited 34
Chelsea Therapeutics, Inc. 35
Yuyu Pharma, Inc. 36
Hisamitsu Pharmaceutical Co., Inc. 37
Theravance, Inc. 38
Suven Life Sciences Ltd. 39
Spectrum Pharmaceuticals, Inc. 40
Curemark, LLC 41
Supernus Pharmaceuticals, Inc. 42
PsychoGenics, Inc. 43
Intra-Cellular Therapies, Inc. 44
Neos Therapeutics, Inc. 45
KemPharm, Inc. 46
Disruptive Behavior Disorder - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
edivoxetine - Drug Profile 53
DSP-225289 - Drug Profile 55
Histamine H3 Receptor Antagonists - Drug Profile 56
brexpiprazole - Drug Profile 57
droxidopa - Drug Profile 59
dextroamphetamine - Drug Profile 62
KP-106 - Drug Profile 63
sofinicline - Drug Profile 65
EGP-119 - Drug Profile 67
ORADUR-ADHD - Drug Profile 68
eltoprazine - Drug Profile 69
(droxidopa + carbidopa) - Drug Profile 70
SUVN-502 - Drug Profile 72
COL-171 - Drug Profile 73
ITI-002 - Drug Profile 74
lisdexamfetamine dimesylate - Drug Profile 75
SPN-812 - Drug Profile 78
guanfacine hydrochloride ER - Drug Profile 79
guanfacine hydrochloride ER - Drug Profile 81
guanfacine hydrochloride ER - Drug Profile 83
CM-4612 - Drug Profile 85
AZD-5213 - Drug Profile 86
YY-162 - Drug Profile 88
ND-0801 - Drug Profile 89
metadoxine ER - Drug Profile 91
molindone - Drug Profile 93
SPI-339 - Drug Profile 94
methylphenidate hydrochloride - Drug Profile 95
TD-9855 - Drug Profile 96
methylphenidate - Drug Profile 97
PD-2005 - Drug Profile 98
PD-2007 - Drug Profile 99
betahistine hydrochloride - Drug Profile 100
Methylphenidate Prodrug - Drug Profile 101
dextroamphetamine ER - Drug Profile 102
EB-1020 - Drug Profile 103
Agmatine - Drug Profile 104
MGS-0028 - Drug Profile 105
dextroamphetamine IR - Drug Profile 106
BNC-375 - Drug Profile 107
BLI-1008 - Drug Profile 108
amfetamine XR - Drug Profile 109
EB-1020 SR - Drug Profile 110
Partial DA/5-HT Receptor Ligands - Drug Profile 111
Disruptive Behavior Disorder Therapeutics - Drug Profile Updates 112
Disruptive Behavior Disorder Therapeutics - Discontinued Products 135
Disruptive Behavior Disorder Therapeutics - Dormant Products 136
Disruptive Behavior Disorder - Product Development Milestones 140
Featured News and Press Releases 140
Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151



List of Tables

Number of Products Under Development for Disruptive Behavior Disorder, H1 2013 12
Products under Development for Disruptive Behavior Disorder - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Development by Companies, H1 2013 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2013 25
DURECT Corporation, H1 2013 26
Johnson and Johnson, H1 2013 27
AstraZeneca PLC, H1 2013 28
Eli Lilly and Company, H1 2013 29
Athersys, Inc., H1 2013 30
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 31
Taisho Pharmaceutical Co., Ltd., H1 2013 32
Egalet a/s, H1 2013 33
Pfizer Inc., H1 2013 34
Shire Plc, H1 2013 35
Collegium Pharmaceutical, Inc., H1 2013 36
Bionomics Limited, H1 2013 37
Chelsea Therapeutics, Inc., H1 2013 38
Yuyu Pharma, Inc., H1 2013 39
Hisamitsu Pharmaceutical Co., Inc., H1 2013 40
Theravance, Inc., H1 2013 41
Suven Life Sciences Ltd., H1 2013 42
Spectrum Pharmaceuticals, Inc., H1 2013 43
Curemark, LLC, H1 2013 44
Supernus Pharmaceuticals, Inc., H1 2013 45
PsychoGenics, Inc., H1 2013 46
Intra-Cellular Therapies, Inc., H1 2013 47
Neos Therapeutics, Inc., H1 2013 48
KemPharm, Inc., H1 2013 49
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Stage and Molecule Type, H1 2013 55
Disruptive Behavior Disorder Therapeutics - Drug Profile Updates 115
Disruptive Behavior Disorder Therapeutics - Discontinued Products 138
Disruptive Behavior Disorder Therapeutics - Dormant Products 139
Disruptive Behavior Disorder Therapeutics - Dormant Products (Contd..1) 140
Disruptive Behavior Disorder Therapeutics - Dormant Products (Contd..2) 141
Disruptive Behavior Disorder Therapeutics - Dormant Products (Contd..3) 142



List of Figures

Number of Products under Development for Disruptive Behavior Disorder, H1 2013 12
Products under Development for Disruptive Behavior Disorder - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51
Assessment by Route of Administration, H1 2013 52
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Molecule Type, H1 2013 54
Assessment by Stage and Molecule Type, H1 2013 55

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.